Head-To-Head Analysis: LENSAR (LNSR) vs. The Competition

LENSAR (NASDAQ:LNSR – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare LENSAR to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, risk, earnings and analyst recommendations.

Insider & Institutional Ownership

40.1% of LENSAR shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares LENSAR and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
LENSAR $58.44 million -$34.28 million -12.28
LENSAR Competitors $1.87 billion $136.27 million 5.73

LENSAR’s peers have higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares LENSAR and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LENSAR 56.07% 1,254.25% 49.13%
LENSAR Competitors -269.88% -187.36% -21.77%

Analyst Ratings

This is a summary of current recommendations for LENSAR and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENSAR 1 0 2 0 2.33
LENSAR Competitors 4320 10603 18404 838 2.46

LENSAR presently has a consensus price target of $11.00, suggesting a potential upside of 124.03%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 23.31%. Given LENSAR’s higher possible upside, research analysts clearly believe LENSAR is more favorable than its peers.

Risk & Volatility

LENSAR has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, LENSAR’s peers have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.

Summary

LENSAR peers beat LENSAR on 7 of the 13 factors compared.

About LENSAR

(Get Free Report)

LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens. The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.

Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.